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A B S T R A C T
The aim of the present study was to develop layered double hydroxide (LDH) nanoparticles
coated with PEGylated phospholipid membrane. By comparing the size distribution and zeta
potential, the weight ratio of LDH to lipid materials which constitute the outside mem-
brane was identified as 2:1. Transmission electron microscopy photographs confirmed the
core-shell structure of PEGylated phospholipid membrane coated LDH (PEG-PLDH)
nanoparticles, and cell cytotoxicity assay showed their good cell viability on Hela and BALB/
C-3T3 cells over the concentration range from 0.5 to 50 μg/mL.
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1. Introduction
Layered double hydroxides (LDHs) constitute a broad family of
lamellar solids which in the last decades have deserved an in-
creasing interest because of their applications in different fields,
such as catalysts [1], traps for anionic pollutants [2], and flame
retardants [3]. In recent years, LDHs are gaining increasing at-
tention as carriers for drug/gene delivery [4]. They are
sometimes named as anionic clays due to the similarities
shared with cationic clays, or hydrotalcite-like materials, as
derived from the natural hydroxycarbonate of Mg and Al [5].
LDHs are a class of anionic lamellar compounds made up
of positively charged brucite-like layers with an interlayer gallery
containing charge compensating anions and water molecules
[6].The LDH composition can be expressed in a general formula
[M2+1−xM3+x(OH)2](A−x·nH2O), where M2+ and M3+ can be most di-
valent and trivalent metal ions andA− any type of anions. Many
studies demonstrated that anticancer drugs [7–9] and genes [9–11]
could be successfully intercalated into the LDH layers.
As a nanocarrier, LDH shows many advantages over
other delivery systems [4]. First, they tend to exhibit low cy-
totoxicity, even at a high dose. In addition, LDH is easily
degraded in the acidic environment, thus endowing it an ad-
vantage of biodegradability, which is also responsible for their
endolysosome escaping behavior. However, positively charged
LDH nanoparticles allow avid association with the negatively
charged plasma proteins, which adversely influences their phar-
macokinetic behavior and reduces their blood residence time.
Besides, we observed that they can easily cause death during
intravenous injection.
Phospholipids have long been perceived as safe materials
to compose drug delivery vehicles because of their superior bio-
compatibility. They could cover on the surface of other solid
nanoparticles [12], and several lipid-coated hybrid carriers have
beendeveloped [13].Very recently,we reported a PEGylatedphos-
pholipid membrane coated LDH (PEG-PLDH) delivery system
with a core-shell structure [14]. This new composite system
showed enhanced therapeutic efficacy and survival rate when
compared tonaked LDHnanoparticles since the positive charges
were shielded by phospholipid membrane. DOPA was chosen
as a membrane material because it readily forms liposomes
[15], and has a negatively charged phosphatidic acid headgroup
which aids in the shielding of positively charged LDH. A PEG–
lipid conjugatewas also included in the leaflet lipids to prolong
the circulation time [12].The pharmacokinetic study and in vivo
antitumor activity of PEG-PLDH nanoparticles have been in-
vestigated; here we report the preparation, properties, as well
as in vitro cell cytotoxicity of this novel delivery system.
2. Materials and methods
2.1. Materials
Dioleoylphosphate (sodium salt) (DOPA), distearoylphos-
phatidylethanolamine- [methoxy(polyethylene glycol)-2000]
(DSPE-PEG2000) and cholesterol (Chol) were purchased from
Avanti Polar Lipids (Alabaster, AL, USA). Dilauroylphos-
phatidylcholine (DLPC), dimyristoylphosphatidylcholine (DMPC),
dipalmitoylphosphocholine (DPPC) and distearoylphos-
phocholine (DSPC) were purchased from Genzyme (Cambridge,
MA, USA). Methotrexate (MTX) was provided by Amresco (USA).
HeLa and BALB/C-3T3 cells purchased from the Laboratory
Animal Center of Sun Yat-sen University (Guangzhou, China)
were cultured with DMEM medium (Sigma-Aldrich, USA)
supplemented with 10% calf serum (Life Technologies, USA).
2.2. Preparation of LDH and LDH-MTX nanoparticles
LDH nanoparticle suspension was prepared with a quick pre-
cipitation and subsequent hydrothermal treatment [16,17]. In
brief, 3.0 mmol of MgCl2 and 1.0 mmol of AlCl3 were dis-
solved in 10 ml deionized water. This salt solution was then
rapidly added to a basic solution (30 ml) containing 6.0 mmol
of NaOH within 5 s to generate the precipitate of LDH. After
being stirred for 10 min in N2 stream at room temperature, the
precipitate was collected via centrifugation and further washed
twice. Henceforth, the washed precipitate was manually dis-
persed in 20 ml of deionized water and placed in a 25 ml
autoclave with Teflon linen, followed by hydrothermal treat-
ment at 100 °C in an oven to get the suspension of LDH
nanoparticles. To achieve methotrexate loaded LDH (LDH-
MTX) nanoparticles, 0.1 mmol of MTX was dissolved in NaOH
before the quick precipitation step.
2.3. Preparation of PEG-PLDH and PEG-PLDH-MTX
nanoparticles
PEG-PLDH or PEG-PLDH-MTX nanoparticle suspension was pre-
pared by self-assembly. Lipid materials were dissolved in CHCl3
and dried under a N2 stream. A trace amount of chloroform
was removed by keeping the lipid film under a vacuum. The
lipid film was hydrated with PBS (pH 7.4) to obtain an empty
liposome suspension. LDH or LDH-MTX nanoparticle suspen-
sion was added to the liposomes. The mixture was sonicated
(in a water bath) using a laboratory ultrasonic cleaning machine
(SB-5200DTN, Ningbo Scientz Biotechnology Co., Ltd. Zheji-
ang, China) at 250 W.
2.4. Size and zeta potential
The average hydrodynamic diameter, polydispersity index (PdI)
and zeta potential of the nanoparticles were determined by
dynamic light scattering using a Malvern Zetasizer Nano ZS90
(Malvern Instruments, Worcestershire, UK). The temperature
of the cell was kept constant at 25 °C. The zeta potential was
calculated from the electrophoretic mobility using the
Smoluchowski equation. Samples of the prepared complexes
were diluted in distilled water and were measured at least three
times. Size results are given as intensity distribution by the
mean diameter with its standard deviation.
2.5. Transmission electron microscopy (TEM)
The particle morphology of LDH and PEG-PLDH was con-
firmed by usingTEM.The samples were put on carbon formvar
coated grids, negatively stained with uranyl acetate 1.5%, and
observed using a JEOL JEM-1400 instrument (JEOL, Japan)
(120 kV).
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2.6. Cell culture
Cells were cultured in DMEM supplemented with 10% calf
serum and antibiotics (streptomycin 100 U/ml, penicillin
100 U/ml) at 37 °C in humidified air with 5% CO2.
2.7. Cell cytotoxicity assay
The cytotoxicity of free MTX, LDH-MTX and PEG-PLDH-MTX
nanoparticles on HeLa or BALB/C-3T3 cells was examined via
cytotoxicity assay. Briefly, cells were seeded in 96-well plates
at a density of 1 × 104 cells per well and incubated for 24 h.Then,
the cells were treated with serial concentrations of free MTX,
LDH-MTX or PEG-PLDH-MTX nanoparticles. After incubation
for certain time, 10 μl of dimethyl thiazolyl diphenyl tetrazo-
lium bromide solution (5 mg/ml) was added to each well and
incubated for 4 h. Finally, the medium was replaced with 150 μl
of dimethylsulfoxide and the optical density was determined
with amicroplate reader at a wavelength of 570 nm in triplicate.
3. Results and discussion
3.1. Preparation of LDH and PEG-PLDH nanoparticles
Layered double hydroxides (LDHs) were prepared by co-
precipitation and subsequent hydrothermal treatment.
Liposomes was achieved by using thin-film hydration method.
Fig. 1 showed the schematic of the self-assembly of PEG-PLDH
nanoparticles. The driving force of self-assembly was the elec-
trostatic interaction between negatively charged segments of
DOPA and positively charged surface of LDH nanoparticles.
3.2. Effect of hydrothermal treatment time on LDH
nanoparticles
Hydrothermal treatment time has potential influence on the
particle sizes and surface charges of LDH nanoparticles. Fig. 2
shows that after 4 or 6 h of heat-treatment at 100 °C, the LDH
particles become very uniform, with a narrow particle size dis-
tribution. However, too short treatment time (2 h) leads to much
bigger particles, indicating the presence of some degrees of ag-
gregation. It seems that 2 h of heat-treatment is not enough
to disperse all aggregates into individual LDH crystallites.
3.3. Optimization of the preparation conditions for
PEG-PLDH nanoparticles
3.3.1. Sonication time
The sonication time in preparation method was investigated
at 0, 1, 5, 10 and 15 min. As shown in Fig. 3, the size distribu-
tion became very uniform after 10 min of sonication.
3.3.2. Weight ratio of LDH to lipid materials
DOPA, DSPC, DSPE-PEG2000 and Chol in the molar ratio of
30:27:3:20 were used to form the lipid membrane. The LDH/
lipids weight ratio was investigated at 0:1, 0.5:1, 1:1 2:1 4:1, 8:1,
16:1 and 32:1. With more and more positively charged LDH
nanoparticles added into the system, the zeta potential in-
creased from −41.8 mV to −14.4 mV (Fig. 4). Meanwhile, the
average size of PEG-PLDH nanoparticles decreased as the LDH/
lipids weight ratio increased from 0:1 to 2:1. Positively charged
LDH nanoparticles could interact with negatively charged DOPA
so that the phospholipid membrane coated tightly on the
surface on LDH nanoparticles. As a result, the particle size de-
creased when LDH nanoparticles mixed with empty liposomes.
However, when the LDH/lipids weight ratio further increased
from 2:1 to 32:1, the average size increased with it. This may
be caused by the exposure of positively charged LDH
nanoparticles which would attract negatively charged PEG-PLDH
Fig. 1 – Schematic of self-assembly of PEG-PLDH
nanoparticles.
Fig. 2 – Effect of hydrothermal treatment time on (A) particle size, polydispersity index and (B) zeta potential of LDH
nanoparticles (mean ± standard deviation, n = 3).
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nanoparticles around them. A proper ratio of LDH to lipid ma-
terials was very important when preparing PEG-PLDH
nanoparticles.Therefore, 2:1 was used as the optimum weight
proportion between LDH and liposomes.
3.3.3. Molar ratio of DSPE-PEG2000 to phospholipids
The amount of phospholipids was fixed at 8 μmol, in which
DOPA was fixed at 3 μmol. DSPE-PEG2000 was added in different
amounts to achieve different molar ratios of DSPE-PEG2000 to
phospholipids (1:20, 2:20, 3:20, 4:20, 6:20 and 8:20). As shown
in Fig. 5, the particle sizes and PdIs were similar when themolar
ratio of DSPE-PEG2000 to phospholipids rises from 1:20 to 4:20.
When the molar ratio of DSPE-PEG2000 to phospholipids was
higher than 4:20, the size distribution became uneven. The
surface charge rises with the DSPE-PEG2000/phospholipids molar
ratio increase. It was probably because DSPE-PEG2000 could form
Fig. 3 – Effect of sonication time on (A) particle size, polydispersity index and (B) zeta potential of PEG-PLDH nanoparticles
(mean ± standard deviation, n = 3).
Fig. 4 – Effect of LDH/lipids weight ratio on (A) particle size, polydispersity index and (B) zeta potential of PEG-PLDH
nanoparticles (mean ± standard deviation, n = 3).
Fig. 5 – Effect of DSPE-PEG2000/phospholipids molar ratio on (A) particle size, polydispersity index and (B) zeta potential of
PEG-PLDH nanoparticles (mean ± standard deviation, n = 3).
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a shielding layer on the outside of the membrane which could
cover the negative charge of DOPA.As a result, 4:20 was chosen
to be the optimal DSPE-PEG2000/phospholipids molar ratio.
3.3.4. Molar ratio of DOPA to phospholipids
The amount of phospholipids was fixed at 8 μmol, and DOPA
was added in different amounts to achieve differentmolar ratios
of DOPA to phospholipids (1:12, 1:6, 1:3, 1:2, 4:5). Fig. 6 showed
that 1:2 was the optimum molar ratio of DOPA to phospho-
lipids. Negatively charged DOPA molecules would repel each
other when composing the phospholipidmembrane.As a result,
too much DOPA may lead to instability. However, the phos-
pholipid membrane couldn’t interact closely with positively
charged LDH nanoparticles without negatively charged DOPA.
Fig. 6 – Effect of DOPA/phospholipids molar ratio on (A) particle size, polydispersity index and (B) zeta potential of
PEG-PLDH nanoparticles (mean ± standard deviation, n = 3).
Fig. 7 – Effect of phospholipid species on (A) particle size, polydispersity index and (B) zeta potential of PEG-PLDH
nanoparticles (mean ± standard deviation, n = 3).
Fig. 8 – TEM images of (A) LDH and (B) PEG-PLDH nanoparticles. Scale bars indicate 200 nm.
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Therefore, the proper molar ratio of DOPA to phospholipids was
a key point to obtain stable PEG-PLDH nanoparticles.
3.3.5. Phospholipid species
The molar ratio of DOPA/DSPC/Chol/DSPE-PEG2000 was fixed at
15:9:10:6, and DSPC was replaced by other three kinds of phos-
pholipids (DLPC, DMPC and DPPC) in the same amount. Fig. 7
showed that the particle size and PdI increased after DSPC was
replaced by other phospholipids, and the zeta potential of
PEG-PLDH nanoparticles decreased at the same time, indicat-
ing that DSPC was the optimal phospholipid.
Fig. 9 – The changes of (A) particle size, (B) polydispersity
index and (C) zeta potential of LDH and PEG-PLDH
nanoparticles during a month (mean ± standard deviation,
n = 3).
Fig. 10 – Cell viability of Hela cells after incubation with
different formulations for (A) 4 h, (B) 24 h or (C) 48 h
(mean ± standard deviation, n = 5).
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In summary, the optimal preparation method was deter-
mined as follows: LDH was heat-treated for 4 h; sonication time
for PEG-PLDH was not less than 10 min; the weight ratio of LDH
to lipid materials was 2:1; the molar ratio of DOPA/DSPC/Chol/
DSPE-PEG2000 was fixed at 15:9:10:6.
3.4. Morphology study of nanoparticles
The particle morphology was investigated with transmission
electron microscopy for LDH and PEG-PLDH. Fig. 8 showed that
the LDH nanoparticles were well-shaped in hexagonal form
while the PEG-PLDH nanoparticles had a core-shell structure.
3.5. Stability study of nanoparticles
We investigated the storage stability of LDH and PEG-PLDH
nanoparticles during 1 month of storage at 4 °C. Fig. 9 showed
the particle size, PdI and zeta potential had little change during
the one-month period,which suggested that both LDH and PEG-
PLDH nanoparticles had a high storage stability at 4 °C.
3.6. Cell viability
In vitro cytotoxicity of LDH, PEG-PLDH,MTX, LDH-MTX and PEG-
PLDH-MTX nanoparticles was evaluated on HeLa and BALB/
C-3T3 cells. The MTX-free nanoparticles showed good cell
viability over the concentration range used in this study, the
cell viability was higher than 90% in all wells (Figs. 10 and 11).
As for MTX formulations, there is no obvious difference between
free MTX, LDH-MTX and PEG-PLDH-MTX.
4. Conclusions
PEG-PLDH nanoparticles were successfully manufactured in a
laboratory-scale. The prepared nanoparticles have small par-
ticle size and uniform size distribution. During the preparation
process, the sonication time, LDH/lipids weight ratio and DSPE-
PEG2000/phospholipids molar ratio were the three key points to
achieve the good quality of PEG-PLDH nanoparticles.
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